Key Highlights

● Pfizer reports third quarter results before the open on Tuesday, November 3.

● Consensus is about 73 cents adjusted EPS on revenue near $15.9 billion, per outside estimates.

● August guidance kept adjusted EPS at $2.80 to $3; COVID revenue cut to $4 billion.

● A $650 million Innovent research charge trims adjusted EPS by about 10 cents.

Pfizer (NYSE:PFE) heads into the final week of October with its third quarter report just days away. Market data published October 27 indicated the drugmaker will release results before the market opens on Tuesday, November 3, followed by a call at 10 a.m. Eastern time. The report will be the first full test of the guidance management reaffirmed in August.

The most recent results are those for the second quarter, issued on August 4. Revenue of about $15 billion beat the consensus then, adjusted earnings per share were 77 cents, and a non-cash impairment of about $4.3 billion pushed the reported result to a small loss. Management raised its revenue range, kept its earnings range, and cut its view of COVID product sales.

What is the setup for Pfizer ahead of November 3?

According to a market preview, consensus expectations are for adjusted earnings of about 73 cents per share and revenue of about $15.86 billion. The company's own full-year guidance, set in August, calls for adjusted earnings per share of $2.80 to $3 and revenue of $60.5 to $62.5 billion.

The central event is the scheduled report itself, and until it arrives the only company-confirmed numbers are those from the second quarter and the guidance issued with it.

What did Pfizer report for the second quarter?

Pfizer said second quarter revenue was about $15 billion, up 3% as reported and 1% on an operational basis, which removes currency effects. Excluding the COVID vaccine Comirnaty and the antiviral Paxlovid, operational growth was 5%, and the company's launched and acquired products grew 18% operationally.

Adjusted diluted earnings per share were 77 cents, compared with 78 cents a year earlier. Reported earnings were a loss of 4 cents per share because of about $4.3 billion of non-cash intangible asset impairments. For the first six months, revenue was about $29.5 billion, up 4%, and adjusted earnings per share were $1.52, down from $1.69.

The pattern is familiar to followers of the company: growth outside COVID products, offset by declining pandemic-related sales and by the gradual loss of exclusivity on older drugs. The impairments show that some acquired assets are expected to deliver less than planned when they were acquired, a reminder that portfolio building has costs as well as benefits.

How did Pfizer change its guidance in August?

The company raised the midpoint of its revenue range by $500 million, to $60.5 to $62.5 billion from $59.5 to $62.5 billion. Non-COVID revenue was expected to be about $1.5 billion better than earlier thinking, while the expectation for COVID product revenue was cut to about $4 billion from about $5 billion.

Adjusted diluted earnings per share guidance was reaffirmed at $2.80 to $3. That range includes a hit of about 10 cents from the Innovent Biologics transaction, which carries a $650 million acquired in-process research and development charge in the third quarter.

Other assumptions included adjusted commercial and administrative expenses of $12.5 to $13.5 billion, adjusted research and development expenses of $10.5 to $11.5 billion, an effective tax rate of about 15% and no share retirement. Because the research charge is booked in the third quarter, it is the main item that could make the coming report look different from a clean run rate.

Where does the Pfizer cost-savings program stand?

In its second quarter release, Pfizer said it expects additional productivity savings of about $2.5 billion from next year through 2029. That adds to earlier cost programs, and the company has framed cost discipline as a way to absorb falling COVID sales and upcoming patent expirations.

Cost cutting has been a major part of Pfizer's story since pandemic-era revenue declined. The savings are meant to protect margins while the company funds research and absorbs the loss of exclusivity on several large products later this decade.

Savings plans have limits. Restructuring costs are often booked in reported results and may exceed expectations, and the savings can be partly reinvested in research or marketing rather than flowing to earnings. The company has not said how much of the planned amount will be retained, so the net effect on earnings is uncertain.

Is the Pfizer dividend covered, and what does the payout look like?

Pfizer pays a quarterly dividend of 43 cents per share, according to market data, with an ex-dividend date of November 6 and payment on December 7. In the first half, the company paid about $4.9 billion in dividends, or 86 cents per share, and made no share retirements.

A market preview calculated a payout ratio well above 100% of trailing reported earnings, a figure inflated by the impairments and other charges that depress reported results. On an adjusted basis, the dividend looks smaller relative to earnings: adjusted earnings per share for the first half were $1.52 against dividends of 86 cents.

The gap between reported and adjusted results is why different sources reach different conclusions about coverage. Cash flow is the better test, and the company reports it in its quarterly filing. The dividend amount comes from the company, while coverage ratios are third-party calculations that depend on which earnings measure is used.

What does the Elrexfio phase three result mean for Pfizer?

Pfizer reported that its phase three MagnetisMM five study of Elrexfio, known generically as elranatamab, met its primary endpoint at a pre-specified interim readout. The study enrolled adults with relapsed or refractory multiple myeloma who had received at least one earlier line of therapy, and it compared Elrexfio alone with a combination of daratumumab, pomalidomide and dexamethasone.

The drug significantly improved progression-free survival, according to blinded independent review, and safety was consistent with the known profile. Overall survival, a key secondary endpoint, was not yet mature. Pfizer said it plans to discuss the results with health authorities and to present detailed data at an upcoming medical meeting.

A positive result in an earlier treatment line could widen the drug's reach if regulators agree, but approvals are not guaranteed, and competition in multiple myeloma is intense. The market preview also mentioned an expanded approval from the Food and Drug Administration for Talzenna in combination with Xtandi. Pipeline news matters for the long term but does not change near-term quarterly numbers.

How are COVID products weighing on Pfizer's numbers?

The cut in expected COVID product revenue to about $4 billion from about $5 billion was the main negative adjustment in August. Comirnaty and Paxlovid have been shrinking since the end of the public health emergency, and the seasonal pattern of vaccinations and antiviral use makes quarterly comparisons volatile.

The third quarter is typically a period when vaccine campaigns are being prepared, with revenue timing dependent on regulatory approvals and government guidance for the autumn season. That timing can shift revenue between the third and fourth quarters, so a miss in one quarter does not necessarily imply a full-year problem.

At the same time, the company's non-COVID products are asked to offset the decline. Management said launched and acquired products grew 18% operationally in the second quarter, which shows that newer drugs are contributing. Whether that growth rate continues will be tested in the coming report.

What challenges and uncertainties surround Pfizer before the report?

Several uncertainties stand out. First, patent expirations on major products later in the decade will remove revenue that new launches must replace. Second, pricing pressure in the United States, including federal negotiations over drug prices, can affect growth. Third, the impairments in the second quarter show the difficulty of translating acquired assets into earnings.

There are also timing questions: the Innovent charge will be visible in the third quarter, and management has said it is included in guidance. Currency movements and the pace of vaccine ordering add further variability.

The quarter will also show how the market views the balance between dividends and reinvestment. With no share retirement planned this year, the company is directing cash toward dividends, debt service, business development and research. The Innovent transaction is one example of the last category, and the $650 million charge is the accounting cost of acquiring in-process research rather than a measure of the product it may eventually produce.

The practical test for the company is execution: delivering launches on schedule, controlling spending and meeting the ranges it published. Each of those can be checked against filings after the fact, which is why the report matters more than previews. Previews rely on estimates collected from outside research desks and can lag changes in company plans, so differences between estimates and reported figures are common and do not by themselves indicate a problem.

None of these factors is new, and the company has discussed most of them in earlier filings. The quarterly report will be read against a backdrop where guidance has already been set, so differences from that guidance, rather than the headline numbers alone, will draw attention.

What should readers look for in the Pfizer report on November 3?

The first items to check are revenue and adjusted earnings per share against the company's guidance and against the consensus figures cited in the preview. The second is whether the full-year ranges are reaffirmed, raised or narrowed. The third is the size of the research charge and any new impairments.

Details on non-COVID growth, cash flow, debt and the pace of cost savings will also be informative, as will commentary on the Elrexfio filing plans. The call is scheduled for 10 a.m. Eastern time.